Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study

Autor: Jithma P. Abeykoon, Shaji Kumar, Jorge J. Castillo, Shirley D'Sa, Efstathios Kastritis, Eric Durot, Encarl Uppal, Pierre Morel, Jonas Paludo, Reema Tawfiq, Shayna Sarosiek, M Olabisi Ogunbiyi, Pascale Cornillet-Lefebvre, Robert A. Kyle, Alain Delmer, Morie A. Gertz, Meletios A. Dimopoulos, Steven P. Treon, Stephen M. Ansell, Prashant Kapoor

Publikováno v: Journal of Clinical Oncology. 40:7566-7566

7566 Background: Parenteral limited-duration BR chemoimmunotherapy and continuous orally administered Ibr, a Bruton tyrosine kinase inhibitor, dominate the treatment landscape of WM, a rare B cell lymphoma. No trials have assessed the comparative eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f3279a0304c0bde07ed80ccf0e9062f3
https://doi.org/10.1200/jco.2022.40.16_suppl.7566

Medical Students’ Corner: Barriers to Communication During the COVID-19 Pandemic (Preprint)

Autor: Emma Obiri-Darko, M. Olabisi Ogunbiyi

UNSTRUCTURED The COVID-19 pandemic has inspired us, as medical students, to reflect upon the communication training we have received in medical school and the obstacles we have faced in the clinic due to COVID-19. We hold the view that our communicat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::600ccf0f0f9134b6fe2b7fcd6d25144f
https://doi.org/10.2196/preprints.24989

Acute and chronic effects of Δ

Autor: M Olabisi, Ogunbiyi, Chandni, Hindocha, Tom P, Freeman, Michael A P, Bloomfield

Publikováno v: Progress in neuro-psychopharmacologybiological psychiatry. 101

Acute and chronic exposure to cannabis and its main psychoactive component, Δ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f5f25cf051a6011ad14875f0adb3ea82
https://pubmed.ncbi.nlm.nih.gov/32109508

The neuropsychopharmacology of cannabis:a review of human imaging studies

Autor: Matthew B. Wall, Sebastian F. Green, Katherine Petrilli, M Olabisi Ogunbiyi, Michael A P Bloomfield, Tom P. Freeman, Matthijs G. Bossong, Harry Costello, Rachel Lees, Chandni Hindocha

Publikováno v: Bloomfield, M A P, Hindocha, C, Green, S F, Wall, M B, Lees, R, Petrilli, K, Costello, H, Olabisi Ogunbiyi, M, Bossong, M G & Freeman, T P 2018, ' The neuropsychopharmacology of cannabis : a review of human imaging studies ', Pharmacology and Therapeutics . https://doi.org/10.1016/j.pharmthera.2018.10.006
Pharmacology & Therapeutics
Pharmacology & Therapeutics, 195, 132. Elsevier Inc.
Bloomfield, M A P, Hindocha, C, Green, S F, Wall, M B, Lees, R, Petrilli, K, Costello, H, Olabisi Ogunbiyi, M, Bossong, M G & Freeman, T P 2018, ' The neuropsychopharmacology of cannabis: a review of human imaging studies ', Pharmacology and Therapeutics . https://doi.org/10.1016/j.pharmthera.2018.10.006

The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and TH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f265df89418f7bab5ca3ea4ecff9927
https://kclpure.kcl.ac.uk/ws/files/102173976/The_neuropsychopharmacology_of_cannabis_BLOOMFIELD_Firstonline19October2018_GOLD_AAM_CC_BY_.pdf